Feedback / Questions
TRB-061 - TRex Bio
https://www.businesswire.com/news/home/20250521505737/en/TRexBio-Doses-First-Participant-in-Phase-1-Trial-of-TRB-061-a-Novel-TNFR2-Agonist-for-Atopic-Dermatitis-and-Other-Inflammatory-Diseases
Jun 3, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next